Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of IL-23 inhibition by Skyrizi on psoriasis autoimmunity
2019-004250-28Phase 4Completed
- Sponsor
- Humanitas Research Hospital
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of risankizumab in plaque psoriasis and psoriasis, sponsored by Humanitas Research Hospital. Primary endpoint: Change in activated autoantigen-specific T-cells at week 28. Started Oct 2020; status: completed.
02
Drugs
risankizumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2019-004250-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004250-28.